Search the web
Welcome, Guest
[Sign Out, My Account]
Hoovers

Tuesday, July 22 2014 5:32pm ET - U.S. Markets Closed.
Industry Center
Industry Center > > Genzyme Corporation Company Profile
More On This Industry
· Summary
· News
· Leaders & Laggards
· Company Index
·Industry Browser
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
Need more? Get unbiased, in-depth information on public and private companies worldwide.
  
Genzyme Corporation Company Profile
Genzyme makes big money off uncommon diseases. The company's product portfolio focuses on treatments for multiple sclerosis and rare diseases, including genetic, endocrine, and cardiovascular disease. One of its main products, Cerezyme, is a leading (and pricey) treatment for Gaucher disease, a rare enzyme-deficiency condition. Founded in 1981, Genzyme has treatments for other enzyme disorders including Fabry disease and Pompe disease. In addition, the company conducts research in heart and kidney disease as well as other areas; resulting products would be commercialized by its parent. With operations in the US and Europe, Genzyme was acquired by Sanofi for some $20.1 billion in 2011.
Headlines for Genzyme Corporation
Boston Children's Hospital Announces 2014 Global Pediatric Innovation Summit
- Mon Jun 23
Credit Suisse names vice chairman of healthcare group: memo
- Wed Jul 9
HP interim chair Whitworth steps down, health reasons cited
- Tue Jul 15
Nominations Open for 2014 Global Pediatric Innovator Awards
- Tue Jul 8
HP's interim chair Whitworth resigns to focus on health
- Tue Jul 15
InformedDNA Partners with Edimer Pharmaceuticals to Support XLHED Research
- Tue Jun 24
Cystic Fibrosis Foundation Applauds Successful Phase 3 Results of Ivacaftor (Kalydecoâ„¢) and Lumacaftor (VX-809) Drug ...
- Tue Jun 24
Contact Information
Address: 500 Kendall St.
Cambridge, MA 02142
Phone:617-252-7500
Fax:617-252-7600
Financial Highlights
Fiscal Year End:December
Key People
Chairman: Christopher A. (Chris) Viehbacher
CFO: Marc Esteva
SVP Government Relations: Mary McGrane
Industry Information
Sector:
Industry:
Top Competitors
Amicus Therapeutics, Inc. (fold)
Fresenius SE
Shire plc (shpg)
 


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2014 Morningstar, Inc. All Rights Reserved. Company information © 2014 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2014, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?